Tenaya Therapeutics shares surge 17.39% after-hours as FDA hold on TN-201 lifted and TN-401 interim data show positive results.

Tenaya Therapeutics (NASDAQ:TNYA) surged 17.39% in after-hours trading following the announcement of a $60 million capital raise and extended cash runway, as highlighted in recent analysis from Simply Wall St. and Insider Monkey. The funding, coupled with positive interim data for its cardiac gene therapy candidate TN-401 and the removal of an FDA hold on TN-201, signaled progress in its pipeline and operational resilience. Additionally, a Morgan Stanley report from 10 days prior reinforced optimism, positioning TNYA as a small-to-mid-cap biotech poised for outperformance in 2026. These developments collectively underscored renewed investor confidence in Tenaya’s financial stability and therapeutic ambitions.